MetALD-ALD预测指数:磷脂酰乙醇驱动的生物标志物组合用于识别脂肪性肝病及过量饮酒者
本研究在503名超重/肥胖且患脂肪性肝病的社区成人中开发了基于性别、平均红细胞体积、γ-谷氨酰转移酶、高密度脂蛋白胆固醇和糖化血红蛋白的MAPI指数,用于筛查MetALD-ALD,其AUROC在衍生队列为0.76,在1777人瑞典外部验证队列为0.75。MAPI在所有常用间接酒精生物标志物中表现最佳,可指导PEth确认检测。
要点
- MAPI由性别、MCV、GGT、HDL-C和HbA1c构成,用于筛查MetALD-ALD。
- MAPI在衍生和验证队列的AUROC分别为0.76和0.75。
- MAPI表现优于所有常用间接酒精生物标志物。
核心结论
- MAPI是一种新颖、准确且可扩展的生物标志物组合,用于检测MetALD-ALD。
- MAPI可指导临床实践中的PEth确认检测,并用于缺乏PEth测量的观察性队列研究和临床试验。
研究设计与样本
- 衍生队列为503名居住在南加州的超重/肥胖且患脂肪性肝病的社区成人,均前瞻性接受磁共振成像/磁共振弹性成像评估和PEth检测。
- 采用双向逐步逻辑回归开发最优预测模型,并使用2000次bootstrap样本进行内部验证。
- 外部验证在独立的、基于人群的瑞典队列1777名有PEth测量值的个体中进行。
主要发现
- 衍生队列平均(标准差)年龄为51(13)岁,体重指数为32.9(5.8)kg/m2。
- 最终预测模型MAPI包含性别、平均红细胞体积、γ-谷氨酰转移酶、高密度脂蛋白胆固醇和糖化血红蛋白。
- MAPI在衍生队列和验证队列的AUROC分别为0.76和0.75。
- 基于AUROC,MAPI是所有常用间接酒精生物标志物中表现最佳的模型。
临床怎么用
- MAPI可用于一般人群环境中筛查MetALD-ALD,并指导是否进行PEth确认检测。
- 在缺乏PEth测量的观察性队列研究和临床试验中,可利用MAPI识别MetALD-ALD。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Phosphatidylethanol (PEth) is a direct, objective alcohol biomarker for detecting excessive alcohol use in steatotic liver disease, including metabolic dysfunction and alcohol-associated liver disease (MetALD) and alcohol-associated liver disease (ALD). However, its use in routine clinical practice may be limited by cost and accessibility. This study aimed to develop a novel, accurate, and scalable indirect alcohol biomarker panel to screen for MetALD-ALD in general population settings. METHODS: The derivation cohort consisted of 503 community-dwelling adults with overweight/obesity and steatotic liver disease residing in Southern California, all of whom prospectively underwent magnetic resonance imaging/magnetic resonance elastography assessment and PEth testing. The optimal predictive model was developed using bidirectional stepwise logistic regression and internally validated using 2000 bootstrap samples. The outcome was the presence of MetALD-ALD, defined by incorporating PEth. Model performance was evaluated using area under the receiver operating characteristic curve (AUROC). External validation was conducted in an independent, population-based Swedish cohort of 1777 individuals with available PEth measurements. RESULTS: In the derivation cohort, the mean (standard deviation) age and body mass index were 51 (13) years and 32.9 (5.8) kg/m2, respectively. The final predictive model, termed the MetALD-ALD Prediction Index (MAPI), included sex, mean corpuscular volume, gamma-glutamyltransferase, high-density lipoprotein cholesterol, and hemoglobin A1c. MAPI demonstrated good performance in both derivation and validation cohorts (AUROC, 0.76 and 0.75, respectively). MAPI was the top-performing model among all commonly used indirect alcohol biomarkers, based on AUROC. CONCLUSIONS: MAPI is a novel, accurate, and scalable biomarker panel for detecting MetALD-ALD. MAPI may guide confirmatory PEth testing in clinical practice and be leveraged in observational cohort studies lacking PEth measurements, as well as in clinical trials.
引用
- Tavaglione F, Vaz J, Jamialahmadi O, et al. The MetALD-ALD Prediction Index: A Phosphatidylethanol-Driven Biomarker Panel for Identifying Individuals With Steatotic Liver Disease and Excessive Alcohol Use. Gastroenterology. 2026. PMID: 41739005. doi:10.1053/j.gastro.2025.11.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。